How the VA's Standardize National Baseline Will Force a Strategy Reshape

Bottom Line:

The VA’s Standardized National Baseline mandate consolidates clinical authority, forcing vendors to square their offerings with a singular operational structure and shift field tactics accordingly.

The VA's Standardized National Baseline (SNB) is a transformative initiative poised to redefine how the VA operates and, consequently, how pharmaceutical and medical device manufacturers will need to engage with this health system. This structural shift forces a massive change from a possible site-by-site adoption to one in which manufacturers must approach a system-wide model that is supplemented by high-value local or regional expertise.

Historically, the VA, much like many large organizations, grappled with a degree of operational fragmentation. Individual medical centers and regions developed their own processes, procurement strategies, and even technological solutions to meet local needs, creating variations within the larger health system. While this localized approach allowed for physician preference and custom exceptions, it also created scenarios that were hard for a manufacturer to overcome if its product was not the chosen path. 

The SNB directly addresses these challenges by establishing a common operational framework across all VA facilities. Formally introduced in March 2025 as a centerpiece of the 2026 Electronic Health Record (EHR) rollout acceleration, VA Secretary Doug Collins in March 2025 noted that he expected this shift to standardize 80% to 90% of all workflows, products, and integrations across the VA. Specific to pharmaceutical and medical device manufacturers, products must now align with this singular national framework in addition to achieving formulary status and meeting other core mandates. It is expected that only the most effective clinical solutions will be codified and then spread in a top-down manner to every facility simultaneously, with natural favoritism toward products and solutions that can be broadly adopted across the VA system.  At its core, the SNB serves as a blueprint for standardizing IT infrastructure, data management, and clinical workflows, but the implications for manufacturers will include different market entry considerations and potential changes in existing utilization. Manufacturers capable of offering solutions that align with the SNB's common specifications will gain a distinct advantage.

Although the SNB will reduce bespoke sales strategies for specific facilities, this baseline also creates a critical 10% to 20% window of opportunity. Moreover, manufacturers can ultimately impact the evolution of the SNB, significantly increasing utilization as a new solution spreads throughout the health system. In this context, any achieved exception to the SNB is extremely valuable, as it highlights where specialized therapies or devices provide unique or improved patient outcomes.  Supporting this window of opportunity will require a specific approach with value propositions aligned precisely to show the exceeding of stated clinical goals.

Success in the 2026 landscape requires more than just clinical efficacy. Manufacturers must ensure their offerings meet the latest VA national standards and that any local exceptions at sites slated for 2026 EHR adoption are immediately addressed. By proactively aligning with the SNB, pharmaceutical and medical device leaders can transform a potential barrier into a catalyst for securing a much broader and definitive advantage.